Action Plan — Index
Terms below are listed according to the Action Items in which they may be found. These and other terms may also be found in the Executive Summary, Top Priority Action Items, and Introduction and Overview sections of the document.
|
accreditation 7, 66 |
|
Agency for Healthcare Research and Quality (AHRQ) |
|
|
coordinator 11, 16 |
|
collaborator 21, 22, 34, 40, 62, 66, 68, 73, 76, 79, 80 |
|
agriculture 5, 13, 83, 84 |
|
|
animal and plant health 19, 83 |
|
animal husbandry 50, 83 |
|
farms 17, 18 see also food safety |
|
AHRQ see Agency for Healthcare Research and Quality |
|
American Society for Microbiology (ASM) 43 |
|
antimicrobial drugs |
|
|
availability of 5, 12, 60, 79, 80, 82 |
|
discovery of 12, 80-82 |
|
stimulating resistance 20, 55, 83 |
|
gaps in the arsenal of drugs 5, 74, 75, 79 |
|
monitoring patterns of drug use 3, 4, 5, 22, 67 |
|
overuse and misuse of see appropriate use |
|
prescribing 22, 23, 59, 60 |
|
susceptibility of 3, 8-13, 29-31, 35, 37 |
|
antimicrobial resistance (AR) |
|
|
communities, spread of AR in 63, 78 |
|
emergence of 3, 4, 20, 50, 51, 53, 55, 67, 70, 83-84 |
|
nonfederal partners 62, 63 |
|
the public, and 61-63 |
|
spread of 53, 55, 67, 70 |
|
appropriate use of antimicrobial drugs 21-27, 31-34, 43, 57, 59, 63, 64, 66, 76, 80 |
|
|
promotion of 21, 22, 25, 26, 43, 63, 66, 80 |
|
ASM see American Society for Microbiology |
|
bacteria 17, 18, 20, 33, 35, 46, 50, 52 |
|
behavioral change 24-26, 43 |
|
behavioral interventions see behavioral change |
|
CDC see Centers for Disease Control and Prevention |
|
Centers for Disease Control and Prevention (CDC) |
|
|
coordinator 1-26, 30-33, 35-48, 50, 55-57, 62-66, 68, 79, 80, 83 |
|
collaborator 27, 28, 34, 49, 51-54, 67, 72, 73, 75-78, 81 |
|
CLIA see Clinical Laboratory Improvement Amendments |
|
clinical devices see medical devices and procedures |
|
Clinical Laboratory Improvement Amendments (CLIA) 37 |
|
clinical trials 30, 35, 74, 75, 82 |
|
competitive exclusion products 83 |
|
computer-assisted decision support 24, 26 |
|
confidentiality 3, 5 |
|
consumer groups see consumers |
|
consumer products 5, 42 |
|
consumers 27, 45 |
|
contamination |
|
|
bacterial 46, 52 |
|
environmental 19, 55 see also environmental impact |
|
core capacities 13, 14 |
|
cross-infection see infection |
|
daycare centers 25, 38 |
|
demonstration projects 2, 63 |
|
Department of Defense (DoD) |
|
|
coordinator 64, 65 |
|
collaborator 2, 3, 5, 21, 22, 24, 26, 33, 35, 38-40, 44, 62, 63, 67, 68, 70-78 |
|
Department of Veterans Affairs (DVA) |
|
|
coordinator 64, 65, 69 |
|
|
collaborator 2, 3, 5, 21, 22, 24, 26, 33, 35, 38-41, 44, 48, 62, 63, 67, 68, 72-78 |
|
detection and reporting see surveillance |
|
diagnosis 4, 5, 30 |
|
diagnostic tests and testing 13, 14, 33, 34, 37, 64, 66, 70, 75, 76, 79, 82 |
|
disinfectants 42, 75, 79 |
|
DoD see Department of Defense |
|
drugs see antimicrobial drugs |
|
DVA see Department of Veterans Affairs |
|
economics 11, 34, 80 |
|
electronic surveillance see surveillance |
|
environmental impact 67 see also contamination environmental |
|
Environmental Protection Agency (EPA) |
|
|
coordinator 1, 3, 19, 20, 42, 55, 61 |
|
collaborator 5, 51, 52, 57, 62, 67, 68 |
|
EPA see Environmental Protection Agency |
|
epidemiology 10, 51, 67, 79 |
|
extended care facilities 21, 38, 39 |
|
FDA see Food and Drug Administration |
|
flu see influenza |
|
Food and Drug Administration (FDA) |
|
|
coordinator 1-6, 9, 10, 13, 15, 17, 18, 23, 25-30, 33, 45, 50, 55, 57-60, 62, 68, 69, 72, 73, 76, 77, 79, 80, 82-84 |
|
collaborator 2, 3, 21, 22, 35, 40-42, 48, 49, 51-54, 63, 67, 70, 71, 74, 75, 78, 81 |
|
food safety 6, 17, 45, 46, 49-51, 53, 54, 58, 83 |
|
fungi 35, 67, 76 |
|
genetics see microbial genes and microbial genomics |
|
growth promotants 49 |
|
guidelines, clinical 26, 35 |
|
HCFA see Healthcare Financing Administration |
|
health care delivery 6, 7, 16, 22, 34, 36-42, 44, 63-65 |
|
|
hospitals 21, 22, 24, 41, 48 |
|
managed care 32, 34 |
|
state and local health agencies 13, 14, 62, 63 |
|
Healthcare Financing Administration (HCFA) |
|
|
coordinator 7, 10, 11, 15, 31, 34, 64, 65 |
|
collaborator 2, 3, 8, 22, 24-26, 32, 35-37, 39, 40, 44, 48, 62, 63, 66, 68 |
|
Health Plan Employer Data and Information Set (HEDIS) 32 |
|
Health Resources and Services Administration (HRSA) |
|
|
coordinator 11, 64, 65 |
|
collaborator 3, 26, 31, 34, 35, 39, 40, 44, 62, 63 |
|
HEDIS see Health Plan Employer Data and Information Set |
|
HIV/AIDS 82 |
|
host factors 67 |
|
HRSA see Health Resources and Services Administration |
|
hygienic practices 43 |
|
immunization see vaccine |
|
infection |
|
|
control 39, 44, 64, 66, 75 |
|
transmission 17, 30, 38, 43, 50, 77 |
|
influenza 48, 77 |
|
insurance 36 |
|
JCAHO see Joint Commission on Accreditation of Healthcare Organizations |
|
Joint Commission on Accreditation of Healthcare Organizations (JCAHO) 66 |
|
labeling 4, 9, 29, 30 |
|
laboratories 2-4, 8-10, 12-14, 29, 30, 35, 36, 51 |
|
market incentives 34, 80, 81, 83 |
|
medical devices and procedures 40, 70 |
|
Medicare 24 |
|
microbial |
|
|
ecology 67, 78 |
|
genes 67, 76 |
|
genomics 70 |
|
microbiologists 79 |
|
microbiology 35, 37, 43 |
|
mold see mould |
|
mould 10 |
|
National Committee for Clinical Laboratory Standards (NCCLS) 10, 29 |
|
National Committee for Quality Assurance (NCQA) 66 |
|
National Institutes of Health (NIH) |
|
|
coordinator 10, 33, 62, 67-78, 81, 83 |
|
collaborator 4, 79 |
|
NCCLS see National Committee for Clinical Laboratory Standards |
|
NCQA see National Committee for Quality Assurance |
|
NIH see National Institutes of Health |
|
nongovernment surveillance see surveillance |
|
outcomes see patient outcomes |
|
outpatient 21 |
|
package inserts 27 |
|
parasites 10, 35, 76 |
|
patient outcomes 5, 16, 22, 24, 26, 67 |
|
Peer Review Organizations (PROs) 24 |
|
pesticide use 20, 61 |
|
pharmaceutical companies 74, 79 |
|
pharmacies 6, 48 |
|
pharmacodynamics 74, 82 |
|
pharmacokinetics 74, 82 |
|
pilot programs 80, 83 |
|
pilot studies 2, 19 |
|
pre-clinical studies 74, 82 |
|
Prevention and Control (Focus Area II) 21-66 |
|
Product Development (Focus Area IV) 79-84 |
|
products, new |
|
|
antimicrobials 58, 74, 75, 78, 79, 82-84 |
|
vaccines 77, 78, 82, 83 |
|
proficiency testing programs 8 |
|
PROs see Peer Review Organizations |
|
public health education campaign 25, 43, 45, 46 |
|
quality assurance 7, 14, 26 |
|
reimbursement 31, 34 |
|
regulations 61, 82 |
|
regulatory process 82, 84 |
|
reporting see Surveillance (Focus Area I) |
|
Research (Focus Area III) 67-78 |
|
resistance mechanisms 67 |
|
Surveillance (Focus Area I) 1-20 |
|
surveillance |
|
|
electronic 3 |
|
national plan 2 |
|
nongovernment 2 |
|
susceptibility data see antimicrobial drugs susceptibility |
|
Top Priority Action Items 2, 5, 25, 26, 39, 58, 63, 70, 75-77, 79, 80 |
|
training programs 8, 26, 44, 72 |
|
treatment, novel 48, 70, 74, 75, 78-81 |
|
USDA see U.S. Department of Agriculture |
|
U.S. Department of Agriculture (USDA) |
|
|
coordinator 1-6, 10, 13-15, 17-20, 45, 49-55, 57, 59, 60, 68, 79, 83, 84 |
|
collaborator 2, 3, 25, 62, 63, 67, 70-74, 76-78, 80-82 |
|
vaccination see vaccine |
|
vaccine 47, 48, 64, 66, 77, 78, 79, 82, 83 |
|
veterinary medicine 2, 3, 5, 6, 13-15, 49-61, 63, 76, 77, 80, 83, 84 |
|
viral infection see viruses |
|
viruses 10, 33, 35, 76, 77, 82 |
|
yeast 10 |
<<Previous | Table of Contents | Index
|